8-K/A: Fortrea Corrects Non-GAAP Data, Reports Q1 2024 Results and Provides Updated Guidance

Fortrea Holdings Inc. issued an amended 8-K filing to correct non-GAAP financial information for the trailing twelve months ended March 31, 2024, and provided an updated corporate presentation with Q1 2024 results.

Summary

• Fortrea has corrected administrative errors in non-GAAP information for the trailing twelve months ended March 31, 2024, which was initially presented on May 24, 2024.
• The corrected information is available in an updated corporate presentation furnished on June 7, 2024.
• The company's Q1 2024 results show a revenue of $662.1 million, a decrease of 4.6% compared to Q1 2023.
• Adjusted EBITDA for Q1 2024 was $27.1 million, a decrease of 42.1% compared to Q1 2023.
• The company reported a net loss of $79.8 million for Q1 2024, compared to a net income of $8.0 million in Q1 2023.
• Adjusted net loss for Q1 2024 was $4.9 million, compared to an adjusted net income of $33.0 million in Q1 2023.
• The company's ending backlog was $7.425 billion.
• Free cash flow for Q1 2024 was negative $34.9 million.
• The company's net debt was $1.553 billion as of March 31, 2024.
• Fortrea is progressing towards the divestiture of its Endpoint and Patient Access businesses in Q2.
• The company is targeting to exit 2024 at or around 2022 EBITDA margin levels.
• Full-year 2024 revenue guidance is between $2.785 billion and $2.855 billion.
• Full-year 2024 adjusted EBITDA guidance is between $240 million and $260 million.

Sentiment

Score: 4

Explanation: The document contains a mix of positive and negative information. While the company is making progress on strategic initiatives and has a solid backlog, the significant decline in profitability and negative free cash flow are concerning. The correction of non-GAAP data also raises questions about financial reporting accuracy.

Positives

• Fortrea is actively implementing its growth and differentiation strategies.
• The company is focused on cost structure and margin expansion.
• Approximately 50% of Transition Services Agreements were exited by the end of Q1 2024.
• The company is progressing towards the divestiture of Endpoint and Patient Access businesses in Q2.
• Fortrea is aiming to achieve 2022 EBITDA margin levels by the end of 2024.
• The company reported a book-to-bill ratio of 1.11x for Q1 and 1.22x for the trailing nine months.
• The number and value of RFPs (Requests for Proposals) have increased, indicating solid demand.

Negatives

• Q1 2024 revenue decreased by 4.6% compared to Q1 2023.
• Adjusted EBITDA for Q1 2024 decreased by 42.1% compared to Q1 2023.
• The company reported a net loss of $79.8 million for Q1 2024, a significant downturn from the net income of $8.0 million in Q1 2023.
• Adjusted net loss for Q1 2024 was $4.9 million, compared to an adjusted net income of $33.0 million in Q1 2023.
• Free cash flow was negative $34.9 million for Q1 2024.
• The company has a net debt of $1.553 billion.

Risks

• The company relies on its former parent company for certain services during the transition period.
• There is a dependence on third parties for critical services.
• Establishing new accounting and management systems post-transition could be costly and time-consuming.
• The company has identified existing material weaknesses in its internal control over financial reporting.
• There are risks associated with international operations and currency fluctuations.
• Customer or therapeutic area concentrations could pose a risk.
• Deterioration in the macroeconomic environment could lead to customer defaults or cancellations.
• Backlog may not be indicative of future revenues.
• The company may underprice contracts or overrun cost estimates.
• The divestiture of certain assets may not be completed on time or at all.

Future Outlook

Fortrea expects full-year 2024 revenue to be between $2.785 billion and $2.855 billion and adjusted EBITDA to be between $240 million and $260 million. The company aims to exit 2024 at or around 2022 EBITDA margin levels.

Management Comments

• The company remains committed to exiting 2024 at or around 2022 EBITDA margin levels.
• Fortrea is focused on leveraging its competitive advantages to achieve or exceed market growth rates.
• Management is executing against an SG&A reduction roadmap.

Industry Context

The clinical research industry is competitive, and Fortrea's performance is being evaluated against its peers. The company's focus on cost structure and margin expansion is a common theme in the industry as companies seek to improve profitability. The divestiture of non-core assets is also a trend as companies focus on their core competencies.

Comparison to Industry Standards

• Fortrea's Q1 2024 adjusted EBITDA margin of 4.1% is lower than some of its peers in the CRO industry, such as ICON plc and IQVIA, which typically report margins in the mid-teens.
• The company's revenue decline of 4.6% year-over-year contrasts with some competitors that have shown modest growth in the same period.
• The negative free cash flow of $34.9 million is a concern compared to companies that are generating positive cash flow.
• Fortrea's net debt of $1.553 billion is relatively high compared to some of its peers, which may limit its financial flexibility.
• The company's book-to-bill ratio of 1.11x for Q1 and 1.22x for the trailing nine months is a positive sign, indicating that the company is securing new business at a rate that exceeds its current revenue.

Stakeholder Impact

• Shareholders may be concerned about the decline in profitability and negative free cash flow.
• Employees may be affected by the ongoing restructuring and cost-cutting measures.
• Customers may be impacted by the divestiture of certain business units.
• Creditors may be concerned about the company's high level of net debt.

Next Steps

• The company will continue to execute its growth and differentiation strategies.
• Fortrea will focus on cost structure and margin expansion.
• The company will complete the divestiture of its Endpoint and Patient Access businesses in Q2.
• Fortrea will work towards exiting 2024 at or around 2022 EBITDA margin levels.

Key Dates

Keywords

Fortrea, Clinical Research, CRO, EBITDA, Adjusted EBITDA, Revenue, Backlog, Net Debt, Financial Results, Q1 2024, Divestiture, Non-GAAP, Transition Services Agreement